Nektar Therapeutics (NKTR)

• Market cap: $124M
• 1 day: -2.00%
• 5 days: 8.93%
• 1 month: 8.93%
• 3 months: -11.52%
• 6 months: -41.68%
• Year to date: -22.92%
• 1 year: -49.27%
• 5 years: -96.24%
• 10 years: -92.69%
• Sector: Healthcare
• Industry: Biotechnology

About: Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.

Employees: 61

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

4,260% more call options, than puts

Call options by funds: $218K | Put options by funds: $5K

40% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 15

36% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 36

4% more funds holding

Funds holding: 139 [Q3] → 145 (+6) [Q4]

4.6% less ownership

Funds ownership: 76.64% [Q3] → 72.04% (-4.6%) [Q4]

32% less capital invested

Capital invested by funds: $183M [Q3] → $124M (-$59.3M) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $2 170% upside
• Avg. target: $4.83 553% upside
• High target: $6.50 778% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Jefferies Roger Song 16% 1-year accuracy 3 / 19 met price target	170% upside $2	Buy Upgraded	11 Apr 2025
Oppenheimer Jay Olson 20% 1-year accuracy 16 / 80 met price target	710% upside $6	Outperform Upgraded	14 Mar 2025
HC Wainwright & Co. Arthur He 9% 1-year accuracy 3 / 32 met price target	778% upside $6.50	Buy Reiterated	13 Mar 2025